Journal of Modern OncologyJournal of Modern OncologyСовременная онкология1815-14341815-1442LLC Obyedinennaya Redaktsiya26929ArticlesСтатьиResearch ArticleThe role of angiogenesis blockers in the treatment of metastatic ovarian cancerРоль блокаторов ангиогенеза в терапии метастатического рака яичникаOganianM RОганянМариетта Рафаеловна

врач-ординатор отд-ния онкогинекологии

KazantsevaM VКазанцеваМаргарита Викторовна

канд. мед. наук, глав. врач

DavidenkoI SДавиденкоИрина Сергеевна

д-р мед. наук, зав. отд-нием химиотерапии

PorhanovaN VПорхановаНаталья Владимировна

д-р мед. наук, зав. отд-нием онкогинекологии

ГБУЗ Клинический онкологический диспансер №1 Минздрава Краснодарского края15122013154VOL 15, NO4 (2013)ТОМ 15, №4 (2013)474909042020Copyright ©; 2013, Consilium MedicumCopyright ©; 2013, ООО "Консилиум Медикум"2013Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc/4.0https://modernonco.orscience.ru/1815-1434/article/view/26929

High incidence of ovarian cancer, the identification of the majority of patients in late stages (65–70% – III–IV stage), short-term survival until relapse, repeated following surgeries and chemotherapy determine the necessity of search for effective treatment regimens. Nowadays platinum-based chemotherapy in addition with targeted therapy (bevacizumab) is standard chemotherapy for first and second line of advanced ovarian cancer. To improve the results of survival, further study of the use of bevacizumab in combination with chemotherapy in the subsequent lines of therapy for metastatic ovarian cancer is necessary.

Высокая заболеваемость раком яичника, выявление большинства пациенток в поздних стадиях (65–70% – III–IV стадия), короткий безрецидивный период, неоднократные последующие операции и курсы химиотерапии обусловливают необходимость поиска эффективных режимов терапии. В настоящее время стандартом химиотерапии 1 и 2-й линии распространенного рака яичников является платиносодержащая химиотерапия с добавлением таргетного препарата (бевацизумаб). С целью улучшения результатов выживаемости необходимо дальнейшее изучение использования бевацизумаба в комбинации с химиотерапией в последующих линиях терапии метастатического рака яичника в практике лечебных учреждений Российской Федерации.

metastatic ovarian cancerchemotherapyinhibition of angiogenesisметастатический рак яичникахимиотерапияблокада ангиогенезаДавыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2008 г. Вестн. РОНЦ им. Н.Н.Блохина РАМН. 2010; 21 (Прил. 1).Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96.National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Ovarian Cancer 2013.Du Bois A, Quinn M, Thigpen T et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005; 16 (8S): viii7–12.Ozols R.F, Bundy B.N, Greer B.E et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194–200.Du Bois A, Leck H-J, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first - line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320–9.Ledermann J.A, Raja F. Management strategies for partially platinum - sensitive ovarian cancer. Am J Cancer 2006; 5: 341–54.Bookman M.A. Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 2003; 21: 149s–167s.Harries M, Gore M. Part I: chemotherapy for epithelial ovarian cancer - treatment at first diagnosis. Lancet Oncol 2002; 3: 529–36.Piccart M.J, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin - paclitaxel versus cisplatin - cyclophosphamide in women with advanced epithelial ovarian cancer: three - year results. J Natl Cancer Inst 2000; 92: 699–708.Sullivan B.D, Bicknell R. New molecular pathways in angiogenesis. Br J Cancer 2003; 89: 228–31.Spannuth W.A, Sood A.K, Coleman R.L. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 2008; 5: 194–204.Hartenbach E.M, Olson T.A, Goswitz J.J et al. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 1997; 23: 169–75.Burger R.A. Overview of anti - angiogenic agents in development for ovarian cancer. Gynecol Oncol 2011; 121: 230–8.Kumaran G.C, Jayson G.C, Clamp A.R. Antiangiogenic drugs in ovarian cancer. Br J Cancer 2009; 100: 1–7.Teoh D.G, Secord A.A. Antiangiogenic therapies in epithelial ovarian cancer. Cancer Control 2011; 18: 31–43.Presta L.G, Chen H, O’Conner S.J et al. Humanization of an anti - vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and the other disorders. Cancer Res 1997; 57: 4593–9.Jain R.K. Normalizing tumor vasculature with anti - angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987–9.Sweeney C.J, Miller K.D, Sissons S.E et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001; 61: 3369–72.Kabbinavar F.F, Wong J.T, Ayala R.E et al. The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice [abstract]. Proc Am Assoc Cancer Res 1995; 36: 488.Kanai T, Konno H, Tanaka T et al. Anti - tumor and anti - metastatic effects of human - vascular - endothelial - growth - factor - neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer 1998; 77: 933–6.Perren T, Swartz A.M, Pfisterer J et al. ICON7: A phase III randomised Gynaecologic Cancer Intergroup Trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Ann Oncol 2010; 21 (Suppl. 8). Abstr LBA4.Burger R.A, Brady M.F, Bookman M.A et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol 2010; 28 (Suppl.). Abstr LBA1.Penson R.T, Dizon D.S, Cannistra S.A et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first - line chemotherapy for advanced mullerian tumors. J Clin Oncol 2010; 28: 154–9.Burger R.A, Sill M.W, Monk B.J et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study. J Clin Oncol 2007; 25: 5165– 71.Cannistra S.A, Matulonis U.A, Penson R.T et al. Phase II study of bevacizumab in patients with platinum - resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25: 5180–6.Garcia A.A, Hirte H, Fleming G et al. Phase II clinical trial of bevacizumab and low - dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. J Clin Oncol 2008; 26: 76–82.Mc Gonigle K.F, Muntz H.G, Vuky J et al. Phase II prospective study of weekly topotecan and bevacizumab in platinum - resistant ovarian, primary peritoneal, or fallopian tube cancer (OV). J Clin Oncol 2008; 26 (15S). Abstr 5551.Micha J.P, Goldstein B.H, Rettenmaier M.A et al. A phase II study of outpatient first - line paclitaxel, carboplatin, and bevacizumab for advancedstage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 2007; 17: 771–6.